| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,681 |
11,271 |
$886K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,520 |
8,179 |
$416K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
4,051 |
3,387 |
$230K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,832 |
2,389 |
$165K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
9,996 |
8,821 |
$128K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,413 |
3,801 |
$115K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
525 |
231 |
$86K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,410 |
1,266 |
$85K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
5,366 |
4,735 |
$82K |
| 87631 |
|
1,226 |
671 |
$80K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
565 |
507 |
$55K |
| 99188 |
|
2,824 |
2,305 |
$53K |
| 99383 |
|
578 |
508 |
$41K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,081 |
912 |
$38K |
| 99381 |
|
548 |
500 |
$37K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
512 |
477 |
$36K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,417 |
880 |
$32K |
| 92551 |
|
4,237 |
3,755 |
$30K |
| 99382 |
|
424 |
341 |
$28K |
| 0240U |
|
287 |
173 |
$24K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
598 |
238 |
$23K |
| 54450 |
|
396 |
352 |
$21K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
844 |
767 |
$19K |
| 69210 |
|
914 |
533 |
$19K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
269 |
241 |
$17K |
| 90474 |
|
2,002 |
1,817 |
$16K |
| 83655 |
|
1,995 |
1,383 |
$16K |
| 99215 |
Prolong outpt/office vis |
187 |
151 |
$15K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,004 |
884 |
$12K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
791 |
605 |
$9K |
| 99384 |
|
117 |
105 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
246 |
223 |
$8K |
| 99173 |
|
4,469 |
3,746 |
$7K |
| 54150 |
|
56 |
50 |
$6K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
65 |
64 |
$5K |
| 94664 |
|
630 |
487 |
$5K |
| 85018 |
|
2,377 |
1,703 |
$4K |
| 0071A |
|
77 |
60 |
$3K |
| 0002A |
|
93 |
75 |
$3K |
| 0072A |
|
66 |
54 |
$3K |
| 99460 |
|
64 |
56 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
205 |
160 |
$2K |
| 87807 |
|
148 |
126 |
$2K |
| 0001A |
|
56 |
49 |
$2K |
| 96160 |
|
449 |
358 |
$2K |
| 90620 |
|
140 |
112 |
$2K |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
12 |
12 |
$2K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
34 |
29 |
$1K |
| 36416 |
|
1,757 |
1,116 |
$944.12 |
| 17250 |
|
17 |
13 |
$833.12 |
| 90686 |
|
4,161 |
3,580 |
$449.28 |
| A7016 |
Dome and mouthpiece, used with small volume ultrasonic nebulizer |
201 |
147 |
$359.45 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
18 |
13 |
$359.31 |
| 81002 |
|
154 |
120 |
$311.97 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
33 |
29 |
$230.00 |
| 96161 |
|
30 |
27 |
$203.50 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
227 |
160 |
$157.29 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
80 |
50 |
$90.08 |
| 94760 |
|
276 |
137 |
$63.53 |
| 97802 |
|
94 |
62 |
$48.18 |
| 90633 |
|
1,634 |
1,376 |
$2.05 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
111 |
67 |
$1.80 |
| 90651 |
|
719 |
591 |
$0.78 |
| 91300 |
|
144 |
122 |
$0.00 |
| 90734 |
|
280 |
206 |
$0.00 |
| 90700 |
|
366 |
310 |
$0.00 |
| 90710 |
|
1,043 |
826 |
$0.00 |
| 90648 |
|
2,914 |
2,479 |
$0.00 |
| 90670 |
|
2,772 |
2,517 |
$0.00 |
| 90681 |
|
18 |
12 |
$0.00 |
| 90715 |
|
131 |
86 |
$0.00 |
| 90707 |
|
25 |
13 |
$0.00 |
| 90671 |
|
44 |
23 |
$0.00 |
| 90680 |
|
1,993 |
1,733 |
$0.00 |
| 90698 |
|
73 |
68 |
$0.00 |
| 90723 |
|
1,978 |
1,793 |
$0.00 |
| 90696 |
|
171 |
145 |
$0.00 |
| 90744 |
|
52 |
43 |
$0.00 |
| 91307 |
|
162 |
121 |
$0.00 |
| 90619 |
|
75 |
65 |
$0.00 |
| 90716 |
|
25 |
13 |
$0.00 |